SUCCESSFUL RESUMPTION OF TRIMETHOPRIM-SULFAMETHOXAZOLE (TS) AFTER ORAL DESENSITIZATION IN PATIENTS WITH CHRONIC GRANULOMATOUS DISEASE (CGD)

Kotera F, Hasui M, Tuji S, Yamamoto A, Taniuchi S, Kobayashi Y

Department of Pediatrics, Kansai Medical University, Osaka, Japan

 

Objective: The purpose of our study is to present successful TS desensitization in patients with CGD who were previously intolerant to TS because of adverse reactions. Patients: The first patient was a 10-year old boy diagnosed at 1 year of age. TS had been attempted 4 times so far, accompanied each time by some adverse reactions: fever, rash, hepatic dysfunction and DIC at 1 year; fever 2 hours after the ingestion at 2 years and 2 months; fever 6 hours after the ingestion of sulfamethoxazole only at 2 years and 4 months; and fever and rash 6 hours after the ingestion of TS at 10 years. The second patient was a 13-year old male diagnosed at 3 years of age. TS was initially given at 1 year of age, which was followed by generalized eruption and fever 2 days after the ingestion. Since then TS had not been prescribed.

Methods: The protocol consisted of starting an initial dose of 0.005g (trimethoprim: 0.4mg, sulfamethoxazole: 2mg) and doubling it twice a day to a full dose of 1g (trimethoprim: 80mg, sulfamethoxazole: 400mg) in 5 days.

Results: The first patient developed fever on the third day and urticaria and rash on the 4th and 5th days, which disappeared spontaneously. The second patient had no adverse reactions. They have received the maintenance TS therapy for 8 and 11 months, respectively, without any other adverse reactions.

Conclusion: Oral desensitization to TS is a safe and useful option in the management of CGD patients who have had adverse reactions.

 

 

 
1531